That's fiddly to calculate for COVID ARDS as waves of COVID infections are difficult to guess. I guess just treat it as growth potential.
As for Non-covid ARDS (the more stable treatment opportunity), assuming pricing is the same as US (which is probably optimistic) royalty revenue for top 5 European countries by population would be about AUD $600M. With less optimistic pricing maybe add AUD $400M royalty revenue.
I've assumed 20% of the moderate and severe cases are treated.
I guess a deal for Europe would most likely be for all of Europe rather than just the top 5 countries.
Depending on P/E used would add $17.55 to $55.28 to the MSB share price.
MSB - Most exciting 6 months, page-402
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
0.020(1.87%) |
Mkt cap ! $1.244B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.11 | $1.07 | $4.338M | 3.980M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 13222 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 61499 | 3 |
View Market Depth
| Last trade - 16.10pm 13/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.09 |
Change
0.020 ( 1.42 %) |
||||
| Open | High | Low | Volume | ||
| $1.08 | $1.11 | $1.07 | 875231 | ||
| Last updated 15.59pm 13/06/2024 ? | |||||
| MSB (ASX) Chart |